No association of MDM2 SNP309 with risk of glioblastoma and prognosis

被引：0
作者：
Soufiane El Hallani
Yannick Marie
Ahmed Idbaih
Mathieu Rodero
Blandine Boisselier
Florence Laigle-Donadey
François Ducray
Jean-Yves Delattre
Marc Sanson
机构：
[1] INSERM,Faculté de Médecine
[2] U711,Laboratoire d’Immunologie Cellulaire
[3] Biologie des Interactions Neurones & Glie,undefined
[4] Université Pierre et Marie Curie,undefined
[5] AP-HP,undefined
[6] Groupe Hospitalier Pitié-Salpêtrière,undefined
[7] Service de Neurologie Mazarin,undefined
[8] INSERM U543,undefined
来源：
Journal of Neuro-Oncology | 2007年 / 85卷
关键词：
Glioblastoma; MDM2; Polymorphism; Prognosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The MDM2 SNP309 variant has been shown to increase MDM2 expression and to be associated with tumor formation. In glioblastomas, the P53/MDM2 pathway is of crucial importance and MDM2 amplification is related to poor prognosis. However, we show here that MDM2 SNP309 is not associated with glioblastoma risk, and is not a prognostic factor.
引用
收藏
页码：241 / 244
页数：3
相关论文
共 191 条
[1]  
Behin A(2003)Primary brain tumours in adults Lancet 361 323-331
[2]  
Hoang-Xuan K(2004)Molecular changes in gliomas Curr Opin Oncol 16 607-613
[3]  
Carpentier AF(2006)Prognostic impact of molecular markers in a series of 220 primary glioblastomas Cancer 106 2218-2223
[4]  
Delattre JY(2004)A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans Cell 119 591-602
[5]  
Sanson M(2007)Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk Gynecol Oncol 104 660-664
[6]  
Thillet J(2006)MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis J Clin Oncol 24 4434-4440
[7]  
Hoang-Xuan K(2006)MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C Clin Cancer Res 12 4867-4871
[8]  
Houillier C(2005)The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma Cancer Res 65 9582-9587
[9]  
Lejeune J(2006)MDM2 T309G polymorphism is associated with bladder cancer Anticancer Res 26 3473-3475
[10]  
Benouaich-Amiel A(2006)No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer Cancer Lett 240 195-197
12345678910